FDA classifies Vitruvia thyroid recall as highest risk due to superpotency

Key points

• The FDA assigned a Class I rating to the Vitruvia thyroid tablet recall, indicating a reasonable probability of serious adverse health consequences or death.
• The recall involves 30 mg thyroid tablets that may be superpotent, meaning they contain more active ingredient than labeled.
• Approximately 1,900 units were distributed nationwide between January and September 2025.
• Patients are advised not to stop taking the medication without consulting a doctor, as abrupt discontinuation can lead to overactive thyroid symptoms.

Background

This follows a pattern of FDA Class I recalls in 2026, including a salmonella egg recall in August and an E. coli blueberry recall in August and September. The Vitruvia recall was initially reported on September 24, 2026, and has now been confirmed as the highest risk level.

Why it matters

Class I recalls represent the most severe safety risk, requiring immediate action. For thyroid patients, superpotent medication can cause dangerous overactive thyroid symptoms, making medical consultation essential before stopping or changing treatment.

What to watch

Patients should contact their healthcare providers for guidance on managing the recall. The FDA may issue further updates on the scope of the recall or additional safety measures.